Hidradenitis suppurativa carries an unusually heavy load of metabolic and behavioural comorbidity. Obesity and smoking are both strongly associated, and both independently alter the circulating immune compartment in the same direction as the disease. Any cohort compared against a conventional healthy donor pool will therefore produce a difference, and a substantial part of that difference will not be the disease.
The comorbidity problem, stated first because it dominates
Obesity produces a low-grade systemic inflammatory state with raised circulating inflammatory cytokines, altered monocyte subset distribution and changes in T cell phenotype. Smoking independently alters neutrophil and monocyte behavior and circulating cytokine levels. Both are strongly over-represented in hidradenitis suppurativa.
A comparison against lean non-smoking healthy donors will therefore report a large inflammatory difference that partly reflects body mass index and tobacco exposure. Matching comparators on both is not a refinement in this indication, it is the difference between a measurement of disease and a measurement of metabolic state. Body mass index and smoking status are both available as donor selection parameters, subject to availability.
Hurley stage is coarse, and that is a known limitation
Hurley staging divides disease into three categories based on the presence of abscesses, sinus tracts and scarring. It is durable and widely used, and it is also a static anatomical description that does not capture current inflammatory activity. A donor with extensive scarring from long-standing disease and a donor in an active flare can occupy the same stage.
Where the readout is inflammatory rather than structural, an activity measure such as lesion counts or a dedicated activity score carries more information than stage alone. Recording both is cheap and lets the analysis choose.
| Variable | What it captures | Why record it |
|---|---|---|
| Hurley stage | Structural severity and scarring | Comparability with most published cohorts |
| Active lesion count | Current inflammatory burden | Tracks the readout most studies actually measure |
| Body mass index | Metabolic inflammatory contribution | Confounds the primary signal directly |
| Smoking status and pack years | Tobacco immune effect | Independent effect in the same direction as disease |
| Current biologic and duration | Pharmacological suppression | Determines which cytokine readouts remain usable |
| Family history | Possible familial variant | Distinguishes a mechanistically distinct minority |
Related product
Disease-state PBMCs. PBMCs from donors with a documented diagnosis, across 24 autoimmune and inflammatory indications.
A familial minority with a different mechanism
A minority of cases are familial and associated with loss of function variants in genes of the gamma-secretase complex, which affects Notch signalling. This group is small but mechanistically distinct from the sporadic majority, in which metabolic and follicular occlusion factors dominate.
Family history is easy to capture and identifies donors who may not belong in a pooled analysis if the study concerns sporadic disease mechanisms. It is one of the few places in this indication where a single question separates a genuinely different biology.
Treatment now suppresses the axes most studies measure
Tumor necrosis factor blockade and interleukin 17 directed therapy are both established in moderate to severe disease. Both act on cytokine axes central to the described pathology, so a treated donor’s cytokine profile reflects the therapy as much as the disease.
Long-term antibiotic therapy, which remains common, is a less obvious confounder worth capturing. Beyond antimicrobial effect, tetracyclines have recognized anti-inflammatory activity, and prolonged antibiotic exposure alters the microbiome in ways that have systemic immune consequences.
What peripheral blood can support
The lesional tissue is where the characteristic biology sits, and it is not routinely available. Peripheral blood supports circulating cytokine profiling, monocyte subset distribution, interleukin 17 producing T cell frequencies, neutrophil-to-lymphocyte ratio as a simple systemic inflammatory index, and signalling capacity under stimulation.
Given the comorbidity load, most of these readouts should be analyzed with body mass index and smoking as covariates rather than assumed away. That is a modelling decision best made before the cohort is assembled, because it determines how many donors per stratum are needed.
Specifying a hidradenitis suppurativa cohort
OrganaBio supplies disease-state donor material across 24 autoimmune and inflammatory indications for research use, covering discovery, drug screening and biomarker work, with a post-thaw viability specification above 80 percent. Donor-matched plasma, serum and PBMCs from the same donor are available, which most suppliers cannot provide. Donor selection can be scoped by disease state, HLA genotype, age, sex, ethnicity, blood type, CMV and EBV status, BMI and smoking status, all subject to availability.
For this indication the parameters worth naming are Hurley stage, an activity measure such as lesion count, body mass index, smoking status, current biologic or long-term antibiotic therapy with duration, and family history.
High-resolution NGS HLA genotyping is performed across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP, and KIR genotyping is included in donor characterization. Where a design needs the same donor sampled more than once, the repeat-collection program covers eligible donors and is not a blanket guarantee for every donor or request.
Related material: what a mononuclear cell preparation contains, how HLA typing resolution is reported, and the cryopreserved PBMC format.
Frequently asked questions
Why is comorbidity matching emphasised so heavily here?
Because obesity and smoking are both strongly associated with the disease and both independently produce systemic inflammatory changes in the same direction. An unmatched healthy comparator will generate an inflammatory difference that is partly metabolic and behavioural rather than disease related.
Is Hurley stage sufficient as a severity measure?
It captures structural severity and scarring but not current inflammatory activity, so a heavily scarred quiescent donor and an actively flaring donor can share a stage. Record an activity measure such as lesion count alongside it.
What distinguishes familial cases?
A minority carry loss of function variants in gamma-secretase complex genes affecting Notch signalling, which is mechanistically distinct from the sporadic majority. Family history is a single question that flags this group.
Does long-term antibiotic therapy need recording?
Yes. Beyond antimicrobial effect, tetracyclines have recognized anti-inflammatory activity, and prolonged exposure alters the microbiome with systemic immune consequences. It is a common and frequently overlooked confounder.
Which readouts work from cryopreserved mononuclear cells?
Circulating cytokine profiling, monocyte subset distribution, interleukin 17 producing T cell frequencies and signalling capacity under stimulation. Analyze them with body mass index and smoking as covariates rather than assuming they are balanced.
How does biologic therapy affect usability?
Tumor necrosis factor and interleukin 17 directed therapies suppress the axes most studies measure, so a treated donor’s cytokine profile reflects therapy as much as disease. Record agent and duration and stratify rather than pool.
What viability specification applies to this material?
Disease-state donor material carries a post-thaw viability specification above 80 percent. That figure applies to the disease-state line specifically and is not carried across from healthy donor products.
Can this material be used for clinical manufacturing?
No. Disease-state donor material is supplied for research use covering discovery, drug screening and biomarker work. Material intended for further manufacturing is a separate cGMP scope with its own agreement and documentation requirements.
Talk to OrganaBio
Sourcing a hidradenitis suppurativa cohort?
Donor selection can be scoped by disease state, HLA genotype and donor characteristics, subject to availability, and donor-matched plasma, serum and PBMCs are available from the same donor. Tell us the parameters your protocol needs and the scientific team will confirm what can be supplied.
